Objective According to some studies, chronic pain imposes a significant burden on individuals and the economy, affecting more than 30% of the global population. However, the relationship between tea intake and chronic pain remains unclear.

Methods This study employed Mendelian randomization (MR) to detect the causal relationship between tea intake and chronic pain. The tea intake was obtained from the UK Biobank. The Multisite chronic pain (MCP) was used as the primary outcome, while chronic widespread pain (CWP) served as the secondary outcome. To assess heterogeneity, we applied Cochran’s Q statistic with IVW methods. Additionally, the MR-Egger intercept test and MR-PRESSO test were performed to detect potential pleiotropy.

Results The results showed that tea intake increased the risk of MCP. Specifically, an increase in tea intake was associated with a higher risk of MCP (OR = 1.088, 95%CI = 1.038-1.141, P < 0.001). However, no causal relationship was found between tea intake and CWP (OR = 1.006, 95%CI = 0.999-1.014, P > 0.05). Furthermore, no reverse causality was observed.

Conclusion Our findings suggested that genetically predicted tea intake was a risk factor for chronic pain. These results may help shed light on the potential health impacts of tea take, providing further insights into its influence on chronic pain.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data are publicly available datasets; therefore, no additional ethical approval was required.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes